Target, Home Depot,...
Health Care: Drugs
Dendreon Corp (DNDN: NASDAQ)
$4.01 0.04 | 1.01%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -393.61M | -337.81M | -439.48M | -220.16M |
| Operating Gains/Losses | 0.00 | 0.00 | 142.57M | 118.76M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -3.34M | -22.86M | -12.68M | 0.00 |
| (Increase) Decrease in Inventories | 2.58M | -17.56M | -17.05M | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 5.04M | -40.00K | 5.59M | 2.02M |
| (Decrease) Increase In Other Current Liabilities | 13.21M | 21.35M | 10.84M | 16.86M |
| (Increase) Decrease In Other Working Capital | 9.46M | 4.75M | -82.00K | -82.00K |
| Other Non-Cash Items | 90.12M | 76.22M | 46.60M | 17.21M |
| Net Cash From Continuing Operations | -208.72M | -242.30M | -267.47M | -85.52M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -208.72M | -242.30M | -267.47M | -85.52M |
| Sale of Property, Plant & Equipment | 43.00M | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -18.75M | -25.42M | -140.76M | -65.91M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -31.05M | -71.82M | -90.11M | -212.11M |
| Issuance of Debt | 0.00 | 607.13M | 0.00 | 3.85M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 4.38M | 9.04M | 83.28M | 646.84M |
| Repayment of Long-Term Debt | -5.44M | -6.57M | -2.64M | -2.75M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 2.14M | -1.38M | 112.00K | 0.00 |
| Net Cash From Financing Activities | 1.08M | 608.22M | 80.75M | 647.94M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -238.69M | 294.10M | -276.83M | 350.31M |
Portfolios with DNDN
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorMost-Active Stocks for the ...
- Usersuresh45
- ContributorStocks Under-$10 Moving Hig...
- Usercarver
- UserZeca
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserLong Term Stock Picks
Latest DNDN Headlines from TheStreet
- A Dendreon Shareholder Voices His Frustration At Incompetent Directors 04.22.13 | 12:04 pm
- Oversold Conditions For Dendreon (DNDN) 04.18.13 | 04:04 pm
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- Cramer's 'Mad Money' Recap: It's Time to Pause 03.21.13 | 08:03 pm
- Shocker! Sell-Sider Admits Dendreon Buy Rating Was Mistake 03.06.13 | 10:03 am
- Why Expect More Price Swings From These 4 Biotechs 02.28.13 | 11:02 am
- Dendreon Corp (DNDN): Today's Featured Drugs Winner 01.28.13 | 05:01 pm
- Seeking Alpha Author Used Multiple Aliases to Tout Biotech Stocks 01.28.13 | 06:01 am
- Biotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS Pharma 01.18.13 | 08:01 am
- Cramer's 6 Stocks in 60 Seconds: CMI CVX PG BUD PRGO DNDN 01.11.13 | 10:01 am
Press Releases for DNDN
- Dendreon Announces Securities Class Action Settlement - Business Wire 03.18.13 | 08:03 am
- Dendreon Announces Webcast Presentation At ROTH Conference - Business Wire 03.12.13 | 07:03 pm
- Dendreon Announces Fourth Quarter And 2012 Year End Results - Business Wire 02.25.13 | 07:02 am
- New PROVENGE® (sipuleucel-T) Data To Be Presented At 2013 American Society Of Clinical Oncology (ASCO) Genitourinary Cancers Symposium - Business Wire 02.13.13 | 08:02 am
- Dendreon To Host Conference Call On February 25 To Announce Fourth Quarter And Full Year 2012 Financial Results And Webcast Presentations At Upcoming Conferences - Business Wire 01.30.13 | 08:01 am
- Dendreon Announces Preliminary Fourth Quarter 2012 Revenues - Business Wire 01.07.13 | 09:01 am
- Dendreon Sells New Jersey Immunotherapy Manufacturing Facility - Business Wire 12.20.12 | 08:12 am
- Dendreon Announces Webcast Presentations At Upcoming Conferences - Business Wire 11.27.12 | 06:11 pm
- Dendreon Appoints Lindsay Rocco To Lead Corporate Communications - Business Wire 11.14.12 | 08:11 am
- Dendreon Announces Third Quarter 2012 Results - Business Wire 11.02.12 | 08:11 am
Partner Headlines for DNDN
- After Hours Most Active for Apr 19, 2013 : PBR/A, CRM, PPL, DOW, GILD, MS, QQQ, EMC, DTV, DNDN, SQNM, YHOO - NASDAQ 04.19.13 | 08:04 pm
- Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind - Seeking Alpha 03.25.13 | 09:03 am
- 6 Reasons To Buy Dendreon Right Now - Seeking Alpha 03.09.13 | 08:03 am
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 02.11.13 | 09:02 am
- Stock Watch Tuesday, 8 January - Seeking Alpha 01.08.13 | 09:01 am
- Stock Watch Thursday, 20 December - Seeking Alpha 12.20.12 | 09:12 am
- Biotech Under The Electron Microscope: What's In The Pipeline And Lessons To Be Learned - Seeking Alpha 12.16.12 | 08:12 am
- Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX) - Benzinga 11.12.12 | 01:11 pm
- The January Effect And 3 Biopharma Stocks - Seeking Alpha 11.09.12 | 09:11 am
- Mid-Afternoon Market Update: Markets Remain Down - Benzinga 11.02.12 | 03:11 pm
